+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID07196579

Personalized KXV01 TCR Lentinvivo Injection Treatment for Adults with Advanced Solid Tumors

Led by TCRx Therapeutics Co.Ltd · Updated on 2026-10-26

30

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a personalized treatment called KXV01 TCR Lentinvivo Injection for adults with advanced solid tumors that no longer respond to standard therapies or for whom no standard treatment exists. This phase 1, open-label, single-arm study aims to assess the safety, tolerability, and initial effectiveness of this lentiviral vector-based therapy carrying the patients own tumor-reactive T-cell receptor. Participants receive the KXV01 TCR Lentinvivo Injection, which is a third-generation, non-replicative lentivirus designed to deliver personalized tumor-fighting T-cell receptors directly into the body. The study involves a dose escalation process to identify safe and tolerable dose levels. Treatment administration and monitoring occur following thorough screening and preparation, including tumor tissue collection to identify reactive TCR sequences. During the study, participants will undergo various assessments to monitor safety and side effects for up to 12 months after treatment, including evaluations of dose-limiting toxicities and adverse events. Researchers will also assess organ function, tumor response, and overall health status. The total participation time spans from screening until safety follow-up, with detailed monitoring to understand the effects and tolerability of the study treatment.

CONDITIONS

Brief Title

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Research Team

J

JingChao Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here